Bayer Aktiengesellschaft (BAYRY) Expected to Announce Earnings on Tuesday

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) is projected to release its results before the market opens on Tuesday, November 11th. Analysts expect Bayer Aktiengesellschaft to post earnings of $0.13 per share and revenue of $11.3055 billion for the quarter.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $0.35 EPS for the quarter, beating analysts’ consensus estimates of $0.25 by $0.10. The company had revenue of $12.42 billion during the quarter, compared to the consensus estimate of $10.79 billion. Bayer Aktiengesellschaft had a negative net margin of 7.61% and a positive return on equity of 15.44%. On average, analysts expect Bayer Aktiengesellschaft to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Bayer Aktiengesellschaft Stock Performance

Shares of BAYRY stock traded up $0.08 during midday trading on Tuesday, hitting $7.64. 172,673 shares of the company were exchanged, compared to its average volume of 719,069. The firm has a market capitalization of $30.02 billion, a P/E ratio of -7.88, a PEG ratio of 3.62 and a beta of 0.90. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.73 and a current ratio of 1.13. The firm’s 50 day moving average price is $8.08 and its two-hundred day moving average price is $7.66. Bayer Aktiengesellschaft has a 52 week low of $4.79 and a 52 week high of $8.70.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on BAYRY. Zacks Research raised shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 30th. Wall Street Zen raised shares of Bayer Aktiengesellschaft from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 19th. Three equities research analysts have rated the stock with a Strong Buy rating and one has assigned a Buy rating to the company’s stock. Based on data from MarketBeat.com, Bayer Aktiengesellschaft has an average rating of “Strong Buy”.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.